Focal segmental glomerulosclerosis: Pathogenesis and treatment

Current Opinion in Pediatrics

Volumn 15, Issue 2, 2003, Pages 171-180

  Benchimol, Corinne ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AZATHIOPRINE; CD2 ANTIGEN; CELL PROTEIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; LOW DENSITY LIPOPROTEIN; LYMPHOKINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEPHRIN; PLACEBO; PLASMA PROTEIN; PREDNISONE; STEROID; TACROLIMUS;

APHERESIS; ASEPTIC NECROSIS; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; CATARACT; CLINICAL FEATURE; CLINICAL TRIAL; CONGENITAL NEPHROTIC SYNDROME; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FOCAL GLOMERULOSCLEROSIS; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; FOLLOW UP; GENE MUTATION; GLOMERULUS FILTRATION; GRAFT FAILURE; GROWTH RETARDATION; HEREDITY; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOADSORPTION; INCIDENCE; INFECTION; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY TRANSPLANTATION; LONG TERM CARE; NEPHROTOXICITY; NONHUMAN; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RELAPSE; REMISSION; REVIEW; SEIZURE; STEROID THERAPY; TREATMENT FAILURE; TUMOR SUPPRESSOR GENE;

ANIMALS; CHILD; CYCLOSPORINE; CYTOTOXICITY, IMMUNOLOGIC; GENES, WILMS TUMOR; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; NEPHROTIC SYNDROME; PLASMAPHERESIS; RENIN;

EID: 0037376485     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200304000-00006     Document Type: Review

References (144)

1. Schwartz MM, Korbet SM: Primary focal segmental glomerulosclerosis: pathology, histological variants, and pathogenesis. Am J Kidney Dis 1993, 22:874-883.
2. Noel LH: Morphological features of primary focal and segmental glomerulosclerosis. Nephrol Dial Transplant 1999, 14:53-57.
3. White RH, Glasgow EF, Mills RJ: Clinicopathological study of nephrotic syndrome in childhood. Lancet 1970, 1:1353-1359.
4. Pei Y, Cattran D, Delmore T, et al.: Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Regional Glomerulonephritis Registry Study. Am J Med 1987, 82:938-944.
5. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 1981, 98:561-564.
6. Beaufils H, Alphonse JC, Guedon J, et al.: Focal glomerulosclerosis: natural history and treatment. A report of 70 cases. Nephron 1978, 21:75-85.
7. Korbet SM, Genchi RM, Borok RZ, et al.: The racial prevalence of glomerular lesions in nephrotic adults. Am J Kidney Dis 1996, 27:647-651.
8. Haas M, Spargo BH, Coventry S: Increasing incidence of focal-segmental glomerulosclerosis among adult nephropathies: a 20-year renal biopsy study. Am J Kidney Dis 1995, 26:740-750.
9. Cameron JS: The enigma of focal segmental glomerulosclerosis. Kidney Int Suppl 1996, 57:S119-S131.
10. D'Agati V: The many masks of focal segmental glomerulosclerosis. Kidney Int 1994, 46:1223-1241.
11. Barisoni L: The changing epidemiology of focal segmental glomerulosclerosis (FSGS) in New York City. Modern Path 1994, 7:156A.
12. Gulati S, Sharma AP, Sharma RK, et al.: Changing trends of histopathology in childhood nephrotic syndrome. Am J Kidney Dis 1999, 34:646-650.
13. Haas M, Meehan SM, Karrison TG, et al.: Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997, 30:621-631.
14. Pontier PJ, Patel TG: Racial differences in the prevalence and presentation of glomerular disease in adults. Clin Nephrol 1994, 42:79-84.
15. Ingulli E, Tejani A: Racial differences in the incidence and renal outcome of idiopathic focal segmental glomerulosclerosis in children. Pediatr Nephrol 1991, 5:393-397.
16. Benfield MR, McDonald R, Sullivan EK, et al.: The 1997 Annual Renal Transplantation in Children Report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1999, 3:152-167.
17. Pinn-Wiggins VW: Nephrotic syndrome in blacks: histopathologic perspectives. Transplant Proc 1987, 19:49-55.
18. Bakir AA, Bazilinski NG, Rhee HL, et al.: Focal segmental glomerulosclerosis. A common entity in nephrotic black adults. Arch Intern Med 1989, 149:1802-1804.
19. Korbet SM, Schwartz MM, Lewis EJ: The prognosis of focal segmental glomerular sclerosis of adulthood. Medicine (Balt) 1986, 65:304-311.
20. Neumayer HH, Kienbaum M, Graf S, et al.: Prevalence and long-term outcome of glomerulonephritis in renal allografts. Am J Kidney Dis 1993, 22:320-325.
21. Dantal J, Baatard R, Hourmant M, et al.: Recurrent nephrotic syndrome following renal transplantation in patients with focal glomerulosclerosis. A one-center study of plasma exchange effects. Transplant 1991, 52:827-831.
22. Tejani A, Stablein DH: Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. J Am Soc Nephrol 1992, 2:S258-S263.
23. Artero M, Biava C, Amend W, et al.: Recurrent focal glomerulosclerosis: natural history and response to therapy. Am J Med 1992, 92:375-383.
24. Abbott KC, Sawyers ES, Oliver JD 3rd, et al.: Graft loss due to recurrent focal segmental glomerulosclerosis in renal transplant recipients in the United States. Am J Kidney Dis 2001, 37:366-373.
25. Seikaly M, Ho PL, Emmett L, et al.: The 12th Annual Report of the North American Pediatric Renal Transplant Cooperative Study: renal transplantation from 1987 through 1998. Pediatr Transplant 2001, 5:215-231.
26. Kashtan CE, McEnery PT, Tejani A, et al.: Renal allograft survival according to primary diagnosis: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 1995, 9:679-684.
27. Glasser RJ, Velosa JA, Michael AF. Experimental model of focal sclerosis. I. Relationship to protein excretion in aminonucleoside nephrosis. Lab Invest 1977, 36:519-526.
28. Shalhoub RJ: Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 1974, 2:556-560.
29. Lagrue G, Xheneumont S, Branellec A, et al.: A vascular permeability factor elaborated from lymphocytes. I. Demonstration in patients with nephrotic syndrome. Biomedicine 1975, 23:37-40.
30. Tomizawa S, Maruyama K, Nagasawa N, et al.: Studies of vascular permeability factor derived from T lymphocytes and inhibitory effect of plasma on its production in minimal change nephrotic syndrome. Nephron 1985, 41:157-160.
31. Bakker WW, van Luijk WH: Do circulating factors play a role in the pathogenesis of minimal change nephrotic syndrome? Pediatr Nephrol 1989, 3:341-349.
32. Levin M, Gascoine P, Turner MT, et al.: A highly cationic protein in plasma and urine of children with steroid-responsive nephrotic syndrome. Kidney Int 1989, 36:867-877.
33. Boulton Jones JM, Tulloch I, Dore B, et al.: Changes in the glomerular capillary wall induced by lymphocyte products and serum of nephrotic patients. Clin Nephrol 1983, 20:72-77.
34. Beale MG, Hoffsten PE, Robson AM, et al.: Inhibitory factors of lymphocyte transformation in sera from patients with minimal change nephrotic syndrome. Clin Nephrol 1980, 13:271-276.
35. Dantal J, Bigot E, Bogers W, et al.: Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994, 330:7-14.
36. Sharma M, Sharma R, McCarthy ET, et al.: The FSGS enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma. J Am Soc Nephrol 1999, 10:552-561.
37. Cheung PK, Stulp B, Immenschuh S, et al.: Is 100KF an isoform of hemopexin? Immunochemical characterization of the vasoactive plasma factor 100KF. J Am Soc Nephrol 1999, 10:1700-1708.
38. Schnaper HW, Aune TM: Identification of the lymphokine soluble immune response suppressor in urine of nephrotic children. J Clin Invest 1985, 76:341-349.
39. Vats A, Nayak A, Ellis D, et al.: Familial nephrotic syndrome: clinical spectrum and linkage to chromosome 19q13. Kidney Int 2000, 57:875-81.
40. Kaplan JM, Kim SH, North KN, et al.: Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 2000, 24:251-256.
41. Winn MP, Conlon PJ, Lynn KL, et al.: Linkage of a gene causing familial focal segmental glomerulosclerosis to chromosome 11 and further evidence of genetic heterogeneity. Genomics 1999, 58:113-20.
42. Boute N, Gribouval O, Roselli S, et al.: NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 2000, 24:349-354.
43. Schwarz K, Simons M, Reiser J, et al. Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin. J Clin Invest 2001, 108:1621-1629.
44. Kestila M, Lenkkeri U, Mannikko M, et al.: Positionally cloned gene for a novel glomerular protein-nephrin-is mutated in congenital nephrotic syndrome. Mol Cell 1998, 1:575-582.
45. Lenkkeri U, Mannikko M, McCready P, et al.: Structure of the gene for congenital nephrotic syndrome of the finnish type (NPHS1) and characterization of mutations. Am J Hum Genet 1999, 64:51-61.
46. Ruotsalainen V, Ljungberg P, Wartiovaara J, et al.: Nephrin is specifically located at the slit diaphragm of glomerular podocytes. Proc Natl Acad Sci USA 1999, 96:7962-7967.
47. Holthofer H, Ahola H, Solin ML, et al.: Nephrin localizes at the podocyte filtration slit area and is characteristically spliced in the human kidney. Am J Pathol 1999, 155:1681-1687.
48. Holzman LB, St, John PL, Kovari IA, et al.: Nephrin localizes to the slit pore of the glomerular epithelial cell. Kidney Int 1999, 56:1481-1491.
49. Shih NY, Li J, Karpitskii V, et al.: Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science 1999, 286:312-315.
50. Mahan JD, Mauer SM, Sibley RK, et al.: Congenital nephrotic syndrome: evolution of medical management and results of renal transplantation. J Pediatr 1984, 105:549-557.
51. Huttunen NP: Congenital nephrotic syndrome of Finnish type. Study of 75 patients. Arch Dis Child 1976, 51:344-348.
52. Call KM, Glaser T, Ito CY, et al.: Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990, 60:509-520.
53. Gessler M, Poustka A, Cavenee W, et al.: Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990, 343:774-778.
54. Pritchard-Jones K, Fleming S, Davidson D, et al.: The candidate Wilms' tumour gene is involved in genitourinary development. Nature 1990, 346:194-197.
55. Armstrong JF, Pritchard-Jones K, Bickmore WA, et al.: 1993. The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo. Mech Dev 1993, 40:85-97.
56. Barbaux S, Niaudet P, Gubler MC, et al.: Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat Genet 1997, 17:467-470.
57. Klamt B, Koziell A, Poulat F, et al.: Frasier syndrome is caused by defective alternative splicing of WT1 leading to an altered ratio of WT1 +/-KTS splice isoforms. Hum Mol Genet 1998, 7:709-714.
58. Pelletier J, Bruening W, Kashtan CE, et al.: Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 1991, 67:437-447.
59. Pelletier J, Bruening W, Li FP, et al.: WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour. Nature 1991, 353:431-434.
60. Little M, Wells C. A clinical overview of WT1 gene mutations. Hum Mutat 1997, 9:209-225.
61. Yoshida H, Kon V, Ichikawa I. Polymorphisms of the renin-angiotensin system genes in progressive renal diseases. Kidney Int 1996, 50:732-744.
62. Yoshida H, Mitarai T, Kawamura T, et al.: Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995, 96:2162-2169.
63. Harden PN, Geddes C, Rowe PA, et al.: Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet 1995, 345:1540-1542.
64. Doria A, Warram JH, Krolewski AS. Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I-converting enzyme gene. Diabetes 1994, 43:690-695.
65. Weber KT: Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair. Semin Nephrol 1997, 17:467-491.
66. Matsusaka T, Hymes J, Ichikawa I. Angiotensin in progressive renal diseases: theory and practice. J Am Soc Nephrol 1996, 7:2025-2043.
67. Rigat B, Hubert C, Alhenc-Gelas F, et al.: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990, 86:1343-1346.
68. Schmidt S, Stier E, Hartung R, et al.: No association of converting enzyme insertion/deletion polymorphism with immunoglobulin A glomerulonephritis. Am J Kidney Dis 1995, 26:727-731.
69. Kunz R, Bork JP, Fritsche L, et al.: Association between the angiotensin-converting enzyme-insertion/deletion polymorphism and diabetic nephropathy: a methodologic appraisal and systematic review. J Am Soc Nephrol 1998, 9:1653-1663.
70. Lee DY, Kim W, Kang SK, et al.: Angiotensin-converting enzyme gene polymorphism in patients with minimal-change nephrotic syndrome and focal segmental glomerulosclerosis. Nephron 1997, 77:471-473.
71. Frishberg Y, Becker-Cohen R, Halle D, et al. Genetic polymorphisms of the renin-angiotensin system and the outcome of focal segmental glomerulosclerosis in children. Kidney Int 1998, 54:1843-1849.
72. Hori C, Hiraoka M, Yoshikawa N, et al.: Significance of ACE genotypes and medical treatments in childhood focal glomerulosclerosis. Nephron 2001, 88:313-319.
73. Rutledge DR, Browe CS, Ross EA: Frequencies of the angiotensinogen gene and angiotensin I converting enzyme (ACE) gene polymorphisms in African Americans. Biochem Mol Biol Int 1994, 34:1271-1275.
74. Habib R, Kleinknecht C: The primary nephrotic syndrome of childhood. Classification and clinicopathologic study of 406 cases. Pathol Annu 1971, 6:417-474.
75. Hyman LR, Burkholder PM. Focal sclerosing glomerulonephropathy with hyalinosis. A clinical and pathologic analysis of the disease in children. J Pediatr 1974, 84:217-225.
76. Nash MA, Greifer I, Olbing H, et al.: 1976. The significance of focal sclerotic lesions of glomeruli in children. J Pediatr 1976, 8:806-813.
77. Newman WJ, Tisher CC, McCoy RC, et al.: Focal glomerular sclerosis: contrasting clinical patterns in children and adults. Medicine (Balt) 1976, 55:67-87.
78. Mongeau JG, Corneille L, Robitaille P, et al.: Primary nephrosis in childhood associated with focal glomerular sclerosis: is long-term prognosis that severe? Kidney Int 1981, 20:743-746.
79. Arbus GS, Poucell S, Bacheyie GS, et al.: Focal segmental glomerulosclerosis with idiopathic nephrotic syndrome: three types of clinical response. J Pediatr 1982, 101:40-45.
80. Focal segmental glomerulosclerosis in children with idiopathic nephrotic syndrome. A report of the Southwest Pediatric Nephrology Study Group. Kidney Int 1985, 27:442-449.
81. Yoshikawa N, Ito H, Akamatsu R, et al.: Focal segmental glomerulosclerosis with and without nephrotic syndrome in children. J Pediatr 1986, 109:65-70.
82. Morita M, White RH, Coad NA, et al.: The clinical significance of the glomerular location of segmental lesions in focal segmental glomerulosclerosis. Clin Nephrol 1990, 33:211-219.
83. Hayslett JP, Krassner LS, Bensch KG, et al.: Progression of lipoid nephrosis to renal insufficiency. N Engl J Med 1969, 281:181-7.
84. Matalon R, Katz L, Gallo G, et al. Glomerular sclerosis in adults with nephrotic syndrome. Ann Intern Med 1974, 80:488-495.
85. Lim VS, Sibley R, Spargo B: Adult lipoid nephrosis: clinicopathological correlations. Ann Intern Med 1974, 81:314-320.
86. Cameron JS, Turner DR, Ogg CS, et al.: The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin Nephrol 1978, 10:213-218.
87. Banfi G, Moriggi M, Sabadini E, et al.: The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol 1991, 36:53-59.
88. Korbet SM, Schwartz MM, Lewis EJ: Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am J Kidney Dis 1994, 23:773-783.
89. Schwartz MM, Korbet SM, Rydell J, et al.: Primary focal segmental glomerular sclerosis in adults: prognostic value of histologic variants. Am J Kidney Dis 1995, 25:845-852.
90. Cattran DC, Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 1998, 32:72-79.
91. Nagai R, Cattran DC, Pei Y. Steroid therapy and prognosis of focal segmental glomerulosclerosis in the erderly. Clin Nephrol 1994, 42:18-21.
92. Ponticelli C, Villa M, Banfi G, et al.: Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis? Am J Kidney Dis 1999, 34:618-625.
93. Mendoza SA, Reznik MA, Griswold WR, et al.: Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents. Pediatr Nephrol 1990, 4:303-307.
94. Tarshish P, Tobin JN, Bernstein J, et al.: Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. Pediatr Nephrol 1996,10:590-593.
95. Aviles DH, Irwin KC, Dublin LS, et al.: Aggressive treatment of severe idiopathic focal segmental glomerulosclerosis. Pediatr Nephrol 1999, 13:298-300.
96. Tune BM, Kirpekar R, Sibley RK, et al.: Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up. Clin Nephrol 1995, 43:84-88.
97. Waldo FB, Benfield MR, Kohaut EC: Methylprednisolone treatment of patients with steroid-resistant nephrotic syndrome. Pediatr Nephrol 1995, 6:503-505.
98. Hoyer PF, Krull F, Brodehl J: Cyclosporin in frequently relapsing minimal change nephrotic syndrome. Lancet 1986, 2:335.
99. Capodicasa G, De Santo NG, Nuzzi F, et al. Cyclosporin A in nephrotic syndrome of childhood-a 14 month experience. Int J Pediatr Nephrol 1986, 7:69-72.
100. Niaudet P, Habib R, Tete MJ, et al.: Cyclosporin in the treatment of idiopathic nephrotic syndrome in chirdren. Pediatr Nephrol 1987, 1:566-573.
101. Meyrier A: Ciclosporin in the treatment of nephrosis. Minimal change disease and focal-segmental glomerulosclerosis. Am J Nephrol 1989, 9:65-71.
102. Neuhaus TJ, Burger HR, Klingler M, et al.: Long-term low-dose cyclosporin A in steroid dependent nephrotic syndrome of childhood. Eur J Pediatr 1992, 151:775-778.
103. Tanaka R, Yoshikawa N, Kitano Y, et al.: Long-term ciclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 1993, 7:249-252.
104. Webb KL, Sargent P, Burke J: Cyclosporin therapy in steroid-dependent nephrotic syndrome. J Paediatr Child Health 1993, 29:188-191.
105. Waldo FB, Kohaut EC: Therapy of focal segmental glomerulosclerosis with cyclosporine A. Pediatr Nephrol 1987, 1:180-182.
106. James RW, Burke JR, Petrie JJ, et al.: Cyclosporin A in the treatment of childhood glomerulonephritis. Aust N Z J Med 1989, 19:198-201.
107. Tejani AT, Butt K, Trachtman H, et al.: Cyclosporine A induced remission of relapsing nephrotic syndrome in children. Kidney Int 1988, 33:729-734.
108. Ingulli E, Tejani A: Severe hypercholesterolemia inhibits cyclosporin A efficacy in a dose-dependent manner in children with nephrotic syndrome. J Am Soc Nephrol 1992, 3:254-259.
109. Walker RG, Kincaid-Smith P: The effect of treatment of corticosteroid-resistant idiopathic (primary) focal and segmental hyalinosis and sclerosis (focal glomerulosclerosis) with ciclosporin. Nephron 1990, 54:117-121.
110. Lieberman KV, Tejani A: A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 1996, 7:56-63.
111. Ponticelli C, Rizzoni G, Edefonti A, et al.: A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993, 43:1377-1384.
112. Cattran DC, Appel GB, Hebert LA, et al.: A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 1999, 56:2220-2226.
113. Ingulli E, Singh A, Baqi N, et al.: Aggressive, long-term cyclosporine therapy for steroid-resistant focal segmental glomerulosclerosis. J Am Soc Nephrol 1995, 5:1820-1825.
114. Meyrier A, Noel LH, Auriche P, et al.: Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie. Kidney Int 1994, 45:1446-1456.
115. Meyrier A, Condamin MC, Broneer D. Treatment of adult idiopathic nephrotic syndrome with cyclosporin A: minimal-change disease and focal-segmental glomerulosclerosis. Collaborative Group of the French Society of Nephrology. Clin Nephrol 1991, 35:S37-S42.
116. Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med 1992, 326:1654-1660.
117. Briggs WA: Treatment of primary glomerulopathies (primary GN) with mycophenolate mofetil (MMF). J Am Soc Nephrol 1998, 9:84A.
118. Briggs WA, Choi MJ, Scheel PJ Jr. Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis. 1998, 31:213-217.
119. Bartosh SM: The use of mycophenolate mofetil in children with nephrotic syndrome. J Am Soc Nephrol 1999, 10:95A.
120. Radhakrishnan J: Mycophenolate mofetil (MMF) treatment of idiopathic focal segmental glomerular sclerosis (FSGS). J Am Soc Nephrol 1999, 10:114A.
121. Al-lehbi AM: Mycophenolate (MMF) in steroid resistant focal segmental glomerulosclerosis (FSGS) (cyclosporine dependent or resistant). J Am Soc Nephrol 199, 10:94A.
122. Montane B: Mycophenolate mofetil (MMF) treatment in steroid resistant/relapsing nephrotic syndrome (NS) of childhood. J Am Soc Nephrol 1999, 10:111A.
123. Choi MJ, Eustace JA, Gimenez LF, et al.: Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002, 61:1098-1114.
124. McCauley J, Shapiro R, Ellis D, et al.: Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 1993, 8:1286-1290.
125. Segarra A, Vila J, Pou L, et al.: Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant 2002, 17:655-662.
126. Savin VJ, Sharma R, Sharma M, et al.: Circulating factor associated with increased glomerular permeability to albumin in recurrent focal Segmental glomerulosclerosis. N Engl J Med 1996, 334:878-883.
127. Zimmerman SW: Plasmapheresis and dipyridamole for recurrent focal glomerular sclerosis. Nephron 1985, 40:241-245.
128. Laufer J, Ettenger RB, Ho WG, et al.: Plasma exchange for recurrent nephrotic syndrome following renal transplantation. Transplantation 1988, 46:540-542.
129. Cochat P, Kassir A, Colon S, et al.: Recurrent nephrotic syndrome after transplantation: early treatment with plasmapheresis and cyclophosphamide. Pediatr Nephrol 1993, 7:50-54.
130. Artero ML, Sharma R, Savin VJ, et al.: Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis 1994, 23:574-581.
131. Mowry J, Marik J, Cohen A, et al.: Treatment of recurrent focal segmental glomerulosclerosis with high-dose cyclosporine A and plasmapheresis. Transplant Proc 1993, 25:1345-1346.
132. Dall'Amico R, Ghiggeri G, Carraro M, et al.: Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children. Am J Kidney Dis 1999, 34:1048-1055.
133. Andresdottir MB, Ajubi N, Croockewit S, et al.: Recurrent focal glomerulosclerosis: natural course and treatment with plasma exchange. Nephrol Dial Transplant 1999, 14:2650-2656.
134. Mitwalli AH: Adding plasmapheresis to corticosteroids and alkylating agents: does it benefit patients with focal segmental glomerulosclerosis? Nephrol Dial Transplant 1998, 13:1524-1528.
135. Feld SM, Figueroa P, Savin V, et al.: Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys. Am J Kidney Dis 1998, 32:230-237.
136. Haas M, Godfrin Y, Oberbauer R, et al.: Plasma immunoadsorption treatment in patients with primary focal and segmental glomerulosclerosis. Nephrol Dial Transplant 1998, 13:2013-2016.
137. Diamond JR, Karnovsky MJ: Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int 1988, 33:917-924.
138. Kasiske BL, O'Donnell MP, Cowardin W, et al.: Lipids and the kidney. Hypertension 1990, 15:443-450.
139. D'Amico G, Gentile MG: Effect of dietary manipulation on the lipid abnormalities and urinary protein loss in nephrotic patients. Miner Electrolyte Metab 1994, 18:203-206.
140. D'Amico G, Gentile MG, Manna G, et al.: Effect of vegetarian soy diet on hyperlipidaemia in nephrotic syndrome. Lancet 1992, 339:1131-1134.
141. Kasiske BL, Velosa JA, Halstenson CE, et al.: The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome. Am J Kidney Dis 1990, 15:8-15.
142. Muso E, Mune M, Fujii Y, et al.: Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome. Kansai-FGS-Apheresis Treatment (KFLAT) Study Group. Kidney Int Suppl 1999, 71:S122-S125.
143. Tune BM, Lieberman E, Mendoza SA: Steroid-resistant nephrotic focal segmental glomerulosclerosis: a treatable disease. Pediatr Nephrol 1996, 10:772-778.
144. Vehaskari VM: Treatment practices of FSGS among North American pediatric nephrologists. Pediatr Nephrol 1999, 13:301-303.